Less than 7% of People with Mental Disorders Receive Effective Treatment
A study in JAMA Psychiatry found that only 6.9% of people with mental disorders across 21 countries receive treatment that meets clinical standards, despite the availability of healthcare.
6.9%: Why Global Psychiatry Is Losing a Battle It Should Have Won Yesterday
The figure 6.9% is not a statistical error but a verdict. A research team led by Daniel Vigo from the University of British Columbia and Harvard Medical School has exposed a system where the "gold standard" of evidence-based medicine has become an unaffordable luxury for 93 out of 100 patients. But behind the dry epidemiological summary lies a much harsher truth about how the psychiatric expertise market works and why digital technologies, despite promises, are not saving the day.
The Core: What Is Really Happening
Vigo's study relies on data from 57,000 respondents across 21 countries and covers a 19-year observation period. The methodology excluded "soft" criteria: it assessed not just whether a patient saw a doctor, but strict adherence to evidence-based medicine standards—adequate therapy duration, correct medication selection, and compliance with clinical guidelines. The result—6.9%—means that psychiatry as a field operates with the efficiency of a 19th-century steam engine.
Media have already circulated a four-step funnel: 46.5% recognize the need for help, 34.1% seek it, 82.9% receive minimal treatment, and 47% of those get effective care. Multiply the fractions—you get 6.9%. Neat arithmetic. But I want to uncover what remains hidden: why, despite massive investments in digital mental health, thousands of startups, and hundreds of millions of venture capital dollars, the situation is not just failing to improve but is structurally entrenched.
Timeline and Context
Vigo's study draws on data from the World Mental Health Surveys—a global WHO initiative launched in the late 1990s covering over 30 countries. In 2025-2026, we observe a paradox: the number of academic publications on digital psychiatry, ML diagnostics, and telemedicine is growing exponentially, yet the effective treatment rate remains stagnant.
Read the January review in World Psychiatry: the authors honestly admit that progress in psychotherapy consists of "cumulative, incremental improvements," not breakthroughs. Digital interventions do show effectiveness comparable to in-person care for depression, anxiety, PTSD, and OCD. But—and this is a critical "but"—they do not solve the main problem: people do not access treatment at all. Over half of patients with a diagnosable disorder do not realize they need help. No app can help someone who considers their melancholy a "personality trait."
Who Wins and Who Loses
Healthcare systems lose. WHO reports a global median of 13 psychiatric workers per 100,000 population. In low-income countries, there are 0.4 psychiatrists and 1.3 nurses per 100,000. Meanwhile, governments allocate an average of 2% of health budgets to mental health, a figure unchanged since 2017. We have a perfect storm: rising morbidity, stagnant funding, and a workforce shortage.
Big tech and digital mental health startups lose. This is a non-obvious insight hidden between the lines. Over the past five years, about $3-4 billion in venture capital has flowed into digital psychiatry. The FDA has approved several breakthrough devices, and cognitive behavioral therapy platforms show efficacy in RCTs. But Vigo's study shows that this entire digital revolution serves a microscopic fraction of patients already in the system. It is not a breakthrough to mass care but an elite product for the motivated and educated.
Winners—and this is alarming—are alternative practices. When 93% of people do not receive effective, science-based care, the market fills with coaches, influencers, and alternative medicine. This is an unregulated space with no standards of effectiveness, but it is where a huge audience not covered by clinical psychiatry flows.
What the Media Leave Out
Insight one: Healthcare fails at mental disorder prevention. Vigo's data clearly show that the bottleneck is not the end of the funnel but the very beginning. 53.5% of patients with diagnosable disorders do not recognize the need for help. This is a problem of psychiatric literacy in the population, but no one wants to pay for its solution. National destigmatization campaigns in Europe and the US are funded on a residual basis—$10-15 million per country per year, a pittance compared to the $1 trillion annual economic burden of depression and anxiety.
Insight two: Effective treatment is expensive, and systems choose not to pay for it. Consider this: the study assessed "effectiveness" based on evidence-based criteria—adequate dosage, duration, and adherence to clinical guidelines. This is resource-intensive. A full CBT program requires 12-16 sessions with a qualified therapist. In the US, that costs $2,500-4,000. Insurance companies have no incentive to cover such volume. They prefer that a patient gets an SSRI prescription and a psychiatrist consultation once every six months—formally "minimally adequate treatment" is met, the box is checked, and the fact that 53% of these patients do not achieve effectiveness criteria is irrelevant because it is not tracked as an insurance KPI.
Insight three: AI in psychiatry is currently monitoring, not diagnosing—a fundamental gap. Studies in Nature Medicine show that ML models can stratify depression subtypes and predict therapy response. Digital phenotyping via smartphones and wearables can indeed detect relapse risk based on patterns of mobility, sleep, and social interactions. But this is all monitoring, not diagnosis. Monitoring provides information but no relief. A system that tells you your stress level is high addresses a person whose cognitive abilities are already impaired by that very stress. This is a vicious cycle that technology has yet to break.
Forecast: Next 30 Days and 90 Days
In the next 30 days, expect reactions from insurance companies to Vigo's publication. Aetna, Kaiser Permanente, and other major US insurers will issue statements about their "commitment to improving access to quality psychiatric care." These will be words. No structural changes in coverage policies will occur because the study contains no direct financial incentive for change.
In the 90-day outlook, I anticipate an announcement of a major public-private partnership between WHO, a big tech company (likely Google Health or Microsoft Nuance), and an academic consortium to develop a "global psychiatric literacy platform." The budget will be around $50-75 million over three years. This will be a response to the main funnel gap—the 53.5% of unaware patients. But the effectiveness of such a partnership is questionable: digital literacy and mental health literacy are different things, and one does not automatically solve the other.
Main forecast: Without structural changes—increasing budgets from 2% to at least 5%, mass training of primary care doctors in psychiatric diagnosis, and implementing stepped care models involving non-specialists—the 6.9% figure will remain a reality even by 2030. Because the problem is not about technology, molecules, or protocols. The problem is that society is not willing to pay the real price for mental health. And 6.9% is exactly what you get when you fund psychiatry on a residual basis and hope that apps and chatbots will fix the situation.
— Editorial Team
